A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …

Guidelines Committee and the sounding board of BSH. It was also placed on the members
section of the BSH website for comment. It has also been reviewed by Royal College of …

Under the auspices of an International Working Group, seven centers submitted diagnostic
and follow-up information on 1545 patients with World Health Organization-defined …

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at
increased risk for thrombotic events. However, no population-based study has estimated this …

Inflammation contributes centrally to cardiovascular diseases, and anti-inflammatory
treatments can reduce cardiovascular events. The JAK–STAT pathway is an emerging target …

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …

Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform
for prospective studies exploring preventive measures. Current risk stratification for …

Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …